Ticagrelor is an antiplatelet medication used to prevent blood clots and to treat conditions such as myocardial infarction and unstable angina. It has shown significantly better outcomes than clopidogrel and is usually preferred in patients who are undergoing percutaneous coronary intervention. Ticagrelor works by reversibly binding to the P2Y12 receptor on platelets and inhibiting adenosine diphosphate-mediated activation and aggregation.

The global ticagrelor market is estimated to be valued at US$ 1285.83 Mn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The ticagrelor market is witnessing growth owing to increasing prevalence of coronary artery diseases worldwide. According to the World Health Organization, coronary artery disease is the leading cause of mortality globally, accounting for over 15 million deaths annually. Key factors responsible for rising cases of CAD include smoking, unhealthy diet, physical inactivity, and obesity. Ticagrelor, with its superior efficacy over clopidogrel, is increasingly being preferred to reduce risk of mortality and morbidity in CAD patients undergoing invasive management. Additionally, ongoing research for developing new formulations of ticagrelor such as novel drug delivery systems and fixed-dose combinations are also expected to boost adoption and support market growth over the forecast period.

SWOT Analysis

Strength: Ticagrelor has demonstrated strong efficacy in reducing cardiovascular events in patients with acute coronary syndromes based on clinical trial results. Being an oral P2Y12 receptor antagonist, it offers convenience of oral administration compared to other antiplatelet therapies like clopidogrel that require activation. The favorable safety and efficacy profile established through extensive clinical research has resulted in ticagrelor becoming the preferred antiplatelet treatment option for ACS patients according to recent guidelines.

Weakness: Ticagrelor is associated with increased risk of bleeding compared to clopidogrel. This includes both minor and major bleeding events. The increased bleeding risk can discourage its use in certain high-risk patients. Additionally, ticagrelor is more expensive than clopidogrel due to its superior clinical profile, which can increase the treatment costs.

Opportunity: The steadily growing disease burden of ACS worldwide presents a large market opportunity for ticagrelor. Expanding Medicaid coverage in the US and improved access to healthcare in developing regions can further drive the demand. Additionally, the patent expiration of clopidogrel in the forecast period is expected to boost the sales of ticagrelor as it is considered a superior substitute. Furthermore, ongoing research on new indications such as stroke and venous thromboembolism can broaden the therapeutic application.

Threats: Increased regulatory scrutiny for safety issues may lead to less frequent prescribing of ticagrelor. The entry of generic versions of clopidogrel once it loses patent protection will intensify price competition in the market. Additionally, the development and approval of newer P2Y12 inhibitors with improved safety profiles can threaten the market position of ticagrelor over the long term.

Key Takeaways

The global Ticagrelor Market Growth is expected to witness high growth over the forecast period owing to the growing disease burden of acute coronary syndromes worldwide. The global ticagrelor market is estimated to be valued at US$ 1285.83 million in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023-2030.

Regionally, North America currently dominates the market and is expected to maintain its leading position throughout the forecast period. This can be attributed to factors like the increasing healthcare expenditure, rising number of PCI procedures, growing obese and diabetic population who are at higher risk of ACS, and favorable reimbursement policies in the US. The European market is projected to witness robust growth due to expanding patient population, availability of comprehensive insurance coverage in major countries, and launch of generic versions of ticagrelor post patent expiry that will make it more affordable. However, regulations limiting medicare spending may restrain the market growth.

The key players operating in the ticagrelor market are Astrazeneca, Pfizer, Bayer, Johnson & Johnson, Boehringer Ingelheim, Merck & Co., and Eli Lilly. Astrazeneca's Brilinta (ticagrelor) holds the leading market share currently. The market is also witnessing the entry of generic versions from companies like An

For more insights, read- https://www.pressreleasebulletin.com/ticagrelor-market-trends-size-and-share-analysis/